Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
639.97B
Market cap639.97B
Price-Earnings ratio
30.87
Price-Earnings ratio30.87
Dividend yield
1.98%
Dividend yield1.98%
Average volume
6.07M
Average volume6.07M
High today
$266.24
High today$266.24
Low today
$260.68
Low today$260.68
Open price
$265.58
Open price$265.58
Volume
2.52M
Volume2.52M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$173.33
52 Week low$173.33

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $265.56, with a market capitalization of 639.97B. The stock trades at a price-to-earnings (P/E) ratio of 30.87 and offers a dividend yield of 1.98%.

During the trading session on 2026-09-15, Johnson & Johnson(JNJ) shares reached a daily high of $266.24 and a low of $260.68. At a current price of $265.56, the stock is +1.9% higher than the low and still -0.3% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 2.52M, versus its average volume of 6.07M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $173.33.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $173.33.

JNJ News

BBC 39m
Man Utd news: How has it come to this for JJ Gabriel? - BBC

...

Man Utd news: How has it come to this for JJ Gabriel? - BBC
Nasdaq 1h
Dow Analyst Moves: JNJ

The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Johnson & Johnso...

Dow Analyst Moves: JNJ
Benzinga 2h
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival

Johnson & Johnson (NYSE:JNJ) on Monday announced new clinical results from its Phase 2b COPERNICUS study evaluating subcutaneous RYBREVANT FASPRO combined with...

Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
25.9%
Sell
3.7%

More JNJ News

Nasdaq 3h
Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson (Symbol: JNJ) is the #10 broker pick, on average, out of the 30 stocks m...

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick
Nasdaq 4h
Dow Movers: JNJ, HONIV

In early trading on Tuesday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up...

Dow Movers: JNJ, HONIV
TipRanks 6h
Nanobiotix assumed with a Buy at Guggenheim

Guggenheim assumed coverage of Nanobiotix (NBTX) with a Buy rating and $64 price target. The firm’s investment thesis is centered on the company’s first-in-clas...

TipRanks 9h
Johnson & Johnson announces new results from COPERNICUS study

Johnson & Johnson announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous Rybrevant Faspro plus Lazcluze, with less frequent dosing...

TipRanks 12h
J&J: Oncology Momentum and Potential $20B DePuy Synthes Divestiture Support Nedelcovych Buy Rating

In a report released yesterday, Michael Nedelcovych from TD Cowen maintained a Buy rating on Johnson & Johnson, with a price target of $300.00. Michael Nedelco...

TipRanks 22h
Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint

The company states: “Contineum (CTNM) Therapeutics announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated impro...

Nasdaq 1d
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition

Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medici...

Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.